Oludotun Adebayo Phillips

List of Publications by Year
in descending order

47	726	623734	552781
papers	citations	14 h-index	26 g-index

52	52	52	818
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Anti-allergic, anti-asthmatic and anti-inflammatory effects of an oxazolidinone hydroxamic acid derivative (PH-251) â€“ A novel dual inhibitor of 5-lipoxygenase and mast cell degranulation. International Immunopharmacology, 2022, 105, 108558.	3.8	3
2	Development and Validation of Stability-Indicating Assay Method for a Novel Oxazolidinone (PH-192) with Anticonvulsant Activity by Using UHPLC-QToF-MS. Molecules, 2022, 27, 1090.	3.8	0
3	GYY4137 attenuates functional impairment of corpus cavernosum and reduces fibrosis in rats with STZ-induced diabetes by inhibiting the TGF-Î²1/Smad/CTGF pathway. Biomedicine and Pharmacotherapy, 2021, 138, 111486.	5.6	4
4	Synthesis and structure-activity relationships of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives as 5-lipoxygenase inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry, 2020, 35, 1471-1482.	5.2	7
5	H2S donor GYY4137 ameliorates paclitaxel-induced neuropathic pain in mice. Biomedicine and Pharmacotherapy, 2020, 127, 110210.	5.6	20
6	Antimicrobial activity and DNA/HSA interaction of fluorinated 3,6,9-trisubstituted acridines. Chemical Papers, 2020, 74, 2327-2337.	2.2	5
7	Anti-progressive Effects of a Series of Glycinyl and Alaninyl Triazolyl-oxazolidinones on Kelly Neuroblastoma Cell Line. Anticancer Research, 2020, 40, 5125-5140.	1.1	2
8	A novel oxazolidinone derivative PH192 demonstrates anticonvulsant activity in vivo in rats and mice. European Journal of Pharmaceutical Sciences, 2019, 130, 21-26.	4.0	7
9	Alleviation of impaired reactivity in the corpus cavernosum of STZ-diabetic rats by slow-release H2S donor GYY4137. International Journal of Impotence Research, 2019, 31, 111-118.	1.8	3
10	Structure-Antibacterial Activity Relationships of N-Substituted-(d-/l-Alaninyl) 1H-1,2,3-Triazolylmethyl Oxazolidinones. Scientia Pharmaceutica, 2018, 86, 42.	2.0	1
11	A validated UPLCâ€“MS/MS method for the analysis of linezolid and a novel oxazolidinone derivative (PH027) in plasma and its application to tissue distribution study in rabbits. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1040, 89-96.	2.3	13
12	Comparative Pharmacokinetic Study for Linezolid and Two Novel Antibacterial Oxazolidinone Derivatives in Rabbits: Can Differences in the Pharmacokinetic Properties Explain the Discrepancies between Their In Vivo and In Vitro Antibacterial Activities?. Pharmaceutics, 2017, 9, 34.	4.5	7
13	Antimycobacterial Activities of N-Substituted-Glycinyl 1H-1,2,3-Triazolyl Oxazolidinones and Analytical Method Development and Validation for a Representative Compound. Scientia Pharmaceutica, 2017, 85, 34.	2.0	8
14	Antiproliferative activity of a series of 5-(1H-1,2,3-triazolyl) methyl- and 5-acetamidomethyl-oxazolidinone derivatives. Molecular Medicine Reports, 2016, 13, 3311-3318.	2.4	9
15	Oxazolidinone antimicrobials: a patent review (2012-2015). Expert Opinion on Therapeutic Patents, 2016, 26, 591-605.	5.0	29
16	Evaluation of the monoamine oxidases inhibitory activity of a small series of 5-(azole)methyl oxazolidinones. European Journal of Pharmaceutical Sciences, 2015, 71, 56-61.	4.0	11
17	Synthesis and biological evaluation of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives. European Journal of Medicinal Chemistry, 2015, 106, 120-131.	5.5	20
18	Evaluation of Anticonvulsant Actions of Dibromophenyl Enaminones Using In Vitro and In Vivo Seizure Models. PLoS ONE, 2014, 9, e99770.	2.5	12

#	Article	IF	Citations
19	Synthesis, neuronal activity and mechanisms of action of halogenated enaminones. European Journal of Medicinal Chemistry, 2014, 76, 20-30.	5.5	13
20	Synthesis and antibacterial activities of N-substituted-glycinyl 1H-1,2,3-triazolyl oxazolidinones. European Journal of Medicinal Chemistry, 2013, 66, 246-257.	5.5	22
21	Novel Actions of Oxazolidinones: In vitro Screening of a Triazolyloxazolidinone for Anticonvulsant Activity. Medical Principles and Practice, 2013, 22, 340-345.	2.4	11
22	Antimycobacterial Activities of Novel 5-(1H-1,2,3-Triazolyl)Methyl Oxazolidinones. Tuberculosis Research and Treatment, 2012, 2012, 1-7.	0.6	8
23	Effects of Varied Substituents on the Antibacterial Activity of Triazolylmethyl Oxazolidinones. Archiv Der Pharmazie, 2012, 345, 790-803.	4.1	8
24	The Effect of Systematic Structural Modifications on the Antibacterial Activity of Novel Oxazolidinones. Medicinal Chemistry, 2011, 7, 45-55.	1.5	7
25	Assessment of the Stability of Novel Antibacterial Triazolyl Oxazolidinones Using a Stability-Indicating High-Performance Liquid Chromatography Method. Medical Principles and Practice, 2011, 20, 51-59.	2.4	5
26	5-Hydroxymethyl-oxazolidin-2-one antibacterials. Expert Opinion on Therapeutic Patents, 2009, 19, 529-540.	5.0	0
27	Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones. European Journal of Medicinal Chemistry, 2009, 44, 3217-3227.	5.5	82
28	Synthesis, antibacterial and anticonvulsant evaluations of some cyclic enaminones. European Journal of Medicinal Chemistry, 2009, 44, 967-975.	5.5	34
29	Synthesis and structureâ€“antibacterial activity of triazolyl oxazolidinones containing long chain acyl moiety. European Journal of Medicinal Chemistry, 2008, 43, 1095-1104.	5.5	30
30	Determination Of Novel Antibacterial Triazolylmethyl Oxazolidinones Concentrations In Human Plasma By APCI-LC-MS: Application To Stability Study. Journal of Pharmacy and Pharmaceutical Sciences, 2008, 11, 22.	2.1	6
31	Pleuromutilin antibacterial agents: patent review 2001 â€“ 2006. Expert Opinion on Therapeutic Patents, 2007, 17, 429-435.	5.0	24
32	Structureâ€“antibacterial activity of arylcarbonyl- and arylsulfonyl-piperazine 5-triazolylmethyl oxazolidinones. European Journal of Medicinal Chemistry, 2007, 42, 214-225.	5.5	38
33	Antihypertensive and vasodilator effects of methanolic and aqueous extracts of Tribulus terrestris in rats. Journal of Ethnopharmacology, 2006, 104, 351-355.	4.1	85
34	Î²-Lactamase inhibitors: a survey of the patent literature 2000 â€“ 2004. Expert Opinion on Therapeutic Patents, 2006, 16, 319-331.	5.0	4
35	Synthesis and biological evaluation of penam sulfones as inhibitors of Î²-lactamases. Bioorganic and Medicinal Chemistry, 2005, 13, 2847-2858.	3.0	8
36	Synthesis and antibacterial activity of new N-linked 5-triazolylmethyl oxazolidinones. Bioorganic and Medicinal Chemistry, 2005, 13, 4113-4123.	3.0	39

#	Article	IF	Citations
37	Antibacterial agents: patent highlights January 2005 to June 2005. Current Opinion in Investigational Drugs, 2005, 6, 768-80.	2.3	0
38	Antibacterial agents: patent highlights January to June 2004. Current Opinion in Investigational Drugs, 2004, 5, 799-808.	2.3	0
39	LC-MS/MS determination of SynercidÂ® injections. Journal of Pharmaceutical and Biomedical Analysis, 2003, 32, 1167-1174.	2.8	22
40	LCâ€“MS/MS Determination of Carbamazepine, Pindolol, and Theophylline in Human Serum. Journal of Liquid Chromatography and Related Technologies, 2003, 26, 1937-1957.	1.0	14
41	Species prevalence and antibacterial resistance of enterococci isolated in Kuwait hospitals. Journal of Medical Microbiology, 2003, 52, 163-168.	1.8	46
42	Antibacterial agents: patent highlights July to December 2002. Current Opinion in Investigational Drugs, 2003, 4, 117-27.	2.3	1
43	Antibacterial agents: patent highlights January to June 2003. Current Opinion in Investigational Drugs, 2003, 4, 926-36.	2.3	0
44	Antibacterial agents: patent highlights January to June 2002. Current Opinion in Investigational Drugs, 2002, 3, 1701-11.	2.3	0
45	Determination of linezolid in human plasma by LC-MS-MS. Analyst, The, 2001, 126, 609-614.	3.5	45
46	Studies on Penam Sulfones. I. Synthesis and .BETA.-Lactamase Inhibitory Activity of 2.BETA.-Alkoxycarbonyl Penicillanic Acid Sulfones.. Journal of Antibiotics, 1996, 49, 944-946.	2.0	5
47	Chemical Modification of Tazobactam. Synthesis of 2.BETA.-((4-Substituted)-1,2,3-triazol-1-yl)methyl Penicillanic Acid Sulfone Derivatives.. Journal of Antibiotics, 1995, 48, 1320-1329.	2.0	8